Advertisement

International Journal of Clinical Pharmacy

, Volume 34, Issue 5, pp 682–685 | Cite as

Preventable drug-related morbidity in community pharmacy: commentary on the implications for practice and policy of a novel intervention

  • Mara Pereira GuerreiroEmail author
  • Ana Paula Martins
  • Judith Anne Cantrill
Commentary

Abstract

This commentary relates to a paper on the development and piloting of a risk management intervention in Portuguese community pharmacy, based on validated preventable drug-related morbidity indicators. In the paper we presented the research programme and implications for future evaluation. However, we believe that the intervention may be seen as important for patient safety without further evaluation. Therefore in this commentary we discuss considerations for service roll-out, by revisiting some issues already presented and by introducing aspects such as service definition and remuneration. We argue that in the absence of service remuneration, redesign of care processes through IT support and inter-professional collaboration, and coaching to encourage the aforementioned efforts it is unlikely that the proposed risk management intervention will succeed in preventing drug-related morbidity.

Keywords

Community pharmacy Indicators Patient safety Portugal Preventable drug-related morbidity 

Notes

Conflicts of interest

None.

References

  1. 1.
    Guerreiro MP, Martins AP, Cantrill JA. Preventable drug-related morbidity in community pharmacy: development and piloting of a complex intervention. Int J Clin Pharm. 2012; published on-line. doi: 10.1007/s11096-012-9625-3.
  2. 2.
    Leape LL, Berwick D, Bates DW. What practices will most improve safety? Evidence-based medicine meets patient safety. JAMA. 2002;288:501–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Avery AJ, Rodgers S, Cantrill JA, Armstrong S, Cresswell K, Eden M, Elliott RA, et al. A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. Lancet. 2012;379(9823):1310–19.Google Scholar
  4. 4.
    Tragni E, Filippi A, Mazzaglia G, Sessa E, Cricelli C, Catapano AL. Monitoring statin safety in primary care. Pharmacoepidemiol Drug Safety. 2007;16:652–7.CrossRefGoogle Scholar
  5. 5.
    Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein A, Andrade SE, et al. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Safety. 2007;16:55–64.CrossRefGoogle Scholar
  6. 6.
    Vainio KK, Airaksinen MS, Hyykky TT, Enlund KH. Effect of therapeutic class on counselling in community pharmacies. Ann Pharmacother. 2002;36:781–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Horne R, Hankins M, Jenkins R. The satisfaction with information about medicines scale (SIMS): a new measurement tool for audit and research. Qual Health Care. 2001;10:135–40.PubMedCrossRefGoogle Scholar
  8. 8.
    Astrom K, Carlsson J, Bates I, Webb DG, Duggan C, Sanghani P, et al. Desire for information about drugs: a multi-method study in general medicine patients. Pharm World Sci. 2000;22:159–64.PubMedCrossRefGoogle Scholar
  9. 9.
    Costa FA, Duggan C, Bates I. Validation of a survey tool for use in cross-cultural studies. Pharmacy Practice. 2008;6:121–7.Google Scholar
  10. 10.
    Morris CJ, Rodgers S, Hammersley VS, Avery AJ, Cantrill JA. Indicators for preventable drug related morbidity: application in primary care. Qual Saf Health Care. 2004;13:181–5.PubMedCrossRefGoogle Scholar
  11. 11.
    MacKinnon NJ, Hepler CD. Preventable drug-related morbidity in older adults—2. Use within a managed care organisation. JMCP 2003; 9:134–41.Google Scholar
  12. 12.
    Government Decree no. 112/2011, 29th November (Decreto-Lei no 112/2011, 29 de Novembro).Google Scholar
  13. 13.
    Roberts AS, Benrimoj SI, Chen TF, Williams KA, Aslani P. Implementing cognitive services in community pharmacy: a review of facilitators used in practice change. Int J Pharm Pract. 2006;14:163–70.CrossRefGoogle Scholar
  14. 14.
    Ministerial Order no. 301/2008, 18th April (Portaria no 301/2008, de 18 de Abril).Google Scholar
  15. 15.
    Roberts AS, Benrimoj SI, Chen TF, Williams KA, Aslani P. Practice change in community pharmacy: quantification of facilitators. Ann Pharmacother. 2008;42:861–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Shah NR, Seger AC, Seger D, Fiskio JM, Kuperman GJ, Blumenfeld B, Recklet EG, Bates DW, Gandhi TK. Improving acceptance of computerized prescribing alerts in ambulatory care. JAMIA 2006; 13: 5–11.Google Scholar
  17. 17.
    Paulino EI, Guerreiro MP, Cantrill JA, Martins AP, Costa FA, Benrimoj SI. Community pharmacists’ and physicians’ inter-professional work—insights from qualitative studies with multiple stakeholders. Rev Port Clin Geral. 2010;26:590–606.Google Scholar
  18. 18.
    Chen TF, Crampton M, Krass I, Benrimoj SI. Collaboration between community pharmacists and GPs in innovative clinical services—a conceptual model. J Soc Adm Pharm. 1999;16:134–43.Google Scholar
  19. 19.
    Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, et al. Which drugs cause preventable hospital admissions to hospital? A systematic review. Br J Clin Pharmacol. 2006;63:136–47.PubMedCrossRefGoogle Scholar
  20. 20.
    Thomsen LA, Winterstein AG, Søndergaard B, Haugbølle LS, Melander A. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother. 2007;41:1411–26.PubMedCrossRefGoogle Scholar
  21. 21.
    Schnipper JL, Rothschild JM. Improving medication safety. Lancet. 2012;379(9823):1278–80.Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Mara Pereira Guerreiro
    • 1
    • 2
    Email author
  • Ana Paula Martins
    • 1
  • Judith Anne Cantrill
    • 3
  1. 1.iMED.UL, Faculdade de Farmácia da Universidade de Lisboa (FFUL)LisbonPortugal
  2. 2.Instituto Superior de Ciências da Saúde Egas Moniz (ISCSEM)Monte da CaparicaPortugal
  3. 3.School of Pharmacy and Pharmaceutical SciencesUniversity of ManchesterManchesterUK

Personalised recommendations